Overview:
Lupus nephritis (LN) is among the most common and serious organ manifestations, developing in roughly 50% of patients with systemic lupus erythmatosus and frequently serving as the initial presentation of disease. Although therapeutic options for LN have expanded, there remain unmet needs. Many patients with LN fail to achieve an adequate response to first-line treatment. Consequently, a substantial proportion progress to chronic kidney disease or kidney failure and face elevated risk for other complications. In response to emerging evidence, clinical practice guidelines—including recently updated recommendations from the American College of Rheumatology (ACR)—have been issued to inform contemporary care. In parallel, advances in the understanding of SLE and LN pathogenesis have driven the development of targeted therapies, resulting in new regulatory approvals and a rapidly evolving treatment paradigm. Together, these developments highlight the need for continuing education designed for rheumatologists, nephrologists, and other clinicians who care for patients with LN.
This symposium will feature recognized clinician-researchers
who will integrate pivotal data with real-world insights drawn from years of
treating patients with LN. Through expert commentary and case-based discussion,
participants will gain a clear insight into current best practices and evolving
evidence to support optimized care for patients with LN.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Apply screening criteria for LN in patients with SLE.
- Evaluate current and emerging therapies for the management of LN in patients with SLE.
- Implement multidisciplinary strategies to deliver evidence-based management of LN